| Name | Title | Contact Details |
|---|
Vizgen is unlocking the power of spatial biomolecule profiling to bring new insight into biological systems and disease.
Bamboo was formed to advance the work of Dr. Richard Jude Samulski, the Director of the Gene Therapy Center at the University of North Carolina (UNC), from the laboratory into human clinical trials where it could meet the requirements for drug approval. Dr. Samulski is a pioneer in the field of gene therapy. Over thirty (30) years ago, Dr. Samulski was the first person to realize the potential to use the adeno-associated virus (AAV) as a vehicle to replace a defective gene with a healthy gene. Since that time, he has re-engineered the naturally occurring virus to target delivery to certain tissues, de-target other tissues, and improve its safety. This has resulted in over twenty (20) patents related to the use of AAV for therapeutic uses. Dr. Samulski continues to lead innovation in the field of vector optimization and AAV re-engineering.
BioStar Ventures continues to build a solid track record as an early-stage, value-added venture investor in disruptive cardiovascular and orthopaedic medical technologies by combining the insight of seasoned venture capitalists with the expertise of world-renowned medical thought leaders in clinical practice to attract unique deal flow, mitigate investment risk, optimize product development, and secure successful exit.
Wolfe Laboratories is a Watertown, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Capital Royalty L.P. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.